Serlopitant

Star0

DB12973InvestigationalSmall molecule

Serlopitant has been investigated for the treatment of Prurigo Nodularis.

Mechanism: Pharmacologically active on Substance-P receptor
Curator reviewed
Formula / weight: C₂₉H₂₈F₇NO₂ · 555.537 g/mol (avg)
Code names: MK-0594 · VPD-737

Resolves to

Compound

UNII277V92K32BCAS860642-69-9ChEMBLCHEMBL447955PubChem23653789

Structure

InChIKeyFLNYCRJBCNNHRH-OIYLJQICSA-NSMILESC[C@@H](O[C@H]1CC[C@@H]2CN(C[C@H]2[C@@H]1C1=CC=C(F)C=C1)C1=CC(=O)CC1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F

Targets

P25103TACR1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

13Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Serlopitant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account